Specific High Affinity Binding of Platelet Activating Factor to Intact Human Blood Neutrophils and Eosinophils

International Archives of Allergy and Immunology

Volumn 110, Issue 2, 1996, Pages 124-131

  Korth, Ruth Maria ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b INSERM   (France)

Author keywords

Eosinophils; Human; Metabolism; Neutrophils; Platelet activating factor; Receptors; Ca2+ i rise

Indexed keywords

APAFANT; PHORBOL 13 ACETATE 12 MYRISTATE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR;

ARTICLE; BLOOD; DESENSITIZATION; EOSINOPHIL; HUMAN; HUMAN CELL; INFLAMMATION; NEUTROPHIL; PHAGOCYTOSIS; PRIORITY JOURNAL;

EID: 0029880648     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000237276     Document Type: Article

References (35)

1. Meade C. Heuer II. Kempe R: Commentary. Biochemical pharmacology of platelet-activating factor (and PAF antagonists) in relation to clinical and experimental thrombocytopenia. Biochcm Pharmacol 1991;41:657-668.
2. Benveniste J. fence M. Varenne P. Bidault J. Boullet C. Polonsky J; Semi-synthèse et structure proposée du facteur activant les plaquettes (PAF): PAF-acéther un alkyl éther analogue de la phosphatidylcholine. C R Acad Sci Paris 1979;289:1037-1040.
3. Demopoulos CA, Pinckard RN, Hanahan DI: Platelet-activating factor: Evidence for l-O-al-kyl-2-acctyl-sn-glyccrol-3-phosphorylcholine as the active component (a new class of lipid mediators). J Biol Client 1979;254:9355-9358.
4. Benveniste J, Henson PM, Cochrane CG: Leukocyte dependent histamine release from rabbit platelets. The role of IgE. basophils and a platelet-activating factor. J Exp Med 1972:136: 1356-1377.
5. Arnoux B. Denjean A. Page CP. Nolible D. Morley J. Benveniste J: Accumulation of platelets and eosinophils in baboon lung after PAF-acether challenge. Am Rev Respir Dis 1988; 137:655-860.
6. Silva PMR. Martins MA. Castro Faria Neto HC. Cordeiro RSB. Vargaftig BB: Generation of an eosinophilotactic activity in the pleural cavity of platelet-activating factor-injected rats. J Pharmacol Exp Thcr 1991;257:1039-1044.
7. Korth RM. Hirafuji M. Benveniste J. Russo-Marie F: Human umbilical vein endothelial cells: Specific binding of platelet-activating factor and cytosolic calcium flux. Biochem Pharmacol 1995:49:1793-1799.
8. Korth R: European Patent No 0312 913. 1987.
9. rO_. release by adherent neutrophil leukocytes. J Immunol 1995;154:1383-1390.
10. Kroegel C. Matthys H: Platelet-activating factor-induced human eosinophil activation. Generation and release of cyclo-oxygenase metabolites in human blood eosinophils from asthmatics. Immunology 1993:78:279-285.
11. Kimani G, Tonncsen MG, Henson PM: Stimulation of eosinophil adherence to human vascular endothelial cells in vitro by platelet-activating factor. J Immunol 1988:14:3161-3166.
12. Beer HJ. Wüthrich B. von Feltcn A: Allergen exposure in acute asthma causes the release of platelet-activating factor (PAF) as demonstrated by the desensitization of platelets to PAF. Int Arch Allergy Immunol 1995;106:291-296.
13. O'Flaherty JTO. Surles JR. Redman J. Jacobsen D. Piantadosi C. Wykle RL: Binding and metabolism of platelet-activating factor by human neutrophils. J Clin Invest 1986;78:381-388.
14. O'Flaherty JT. Jacobsen DP. Redman JF: Bidirectional effects of protein kinase C activators. Studies with human neutrophils and platelet activating factor. J Biol Client 1989:264:6836-6843.
15. Korth R. Benveniste J: BN 52021 displaces [’HJPAF-acethcr from, and inhibits its binding to intact human platelets. Eur J Pharmacol 1987:142:331-341.
16. Korth R, Nunez D, Bidault J, Benveniste J: Comparison of three PAF-acether receptor antagonist ginkgolidcs. Eur J Pharmacol 1988; 152:101-110.
17. Korth R, Hirafuji M, Lalau Keraly C, Delautier D, Bidault J, Benveniste J: Interaction of the PAF antagonist WEB 2086 and its hetrazcpine analogues with human platelets and endothelial cells. Br J Pharmacol 1989;98:653-661.
18. Korth R. Hirafuji M. Bidault J. Canton B. Russo-Marie M. Benveniste J: Comparison between PAF-acether receptors on intact washed human platelets and human endothelial cells in culture; in Catravas JD. Gillis CN. Ryan US (eds): Vascular Endothelium. Receptors and Transduction Mechanisms. New York. Plenum Press, 1989, pp 89-98.
19. Korth R. Middeke M: Long time incubation of monocytic U 937 cells with LDL increases specific PAF-acether binding and the cellular ace-tylhydrolasc activity. Chcm Pliys Lipids 1991: 59:207-213.
20. Chung KF. Dent G. McCusker M. Guinot PH. Page CP. Barnes P.I: Effect of ginkgolides mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet 1987:1:248-251.
21. Saito H. Koshio T. Yanagihara Y. Akiyama K. Shida T: Platelet-activ ating-factor-induced augmentation of production of cosinophil-lineagc cells in hematopoietic precursor cells obtained from human umbilical cord blood, int Arch Allergy AppI Immunol 1993:102:375-382.
22. Mazer B. Domenico J. Sawami II. Gelfand E: Platelet-activating factor induces an increase in intracellular calcium and expression of regulatory' genes in human B lymphoblastoid cell. J Immunol 1991; 146:1914-1920.
23. Honda ZI. Nakamura M. Miki I. Minami M. Watanabe T. Seyama Y. Okado H, Toh H, Ito K, Miyamoto T, Shimizu T: Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature 1991:349:342-346.
24. Sugimoto T. Tsuchimochi H. McGregor CGA. Mutoh H. Shimizu T. Kurachi Y: Molecular cloning and characterization of the platelets-ac-tivating factor receptor gene expressed in the human heart. Biochem Biophys Res Commun 1992:189:617-624.
25. Kroegel C. Yukawa T. Wcstwick J. Barnes PJ: Evidence for two platelet activating factor receptors on eosinophils: Dissociation between PAF-induccd intracellular calcium mobilization degranulation and supcroxidc anion generation in eosinophils. Biochem Biophys Res Commun 1989;162:511-521.
26. Ukena D, Kroegel C, Dent G, Yukawa T, Syb-recht GW, Barnes PJ: PAF-rcccptors on eosinophils: Identification with a novel ligand, I'lIJWEB 2086. Biochcm Pharmacol 1989:38: 1702-1705.
27. Grynkiewicz G. Poenie M. Tsien RY: A new generation of Ca indicators with greatly improved fluorescence properties. J Biol Chem 1985;260:3440-3450.
28. Korth R, Benveniste J: Lysopaf-acether (lyso-paf) binding sites in human neutrophils (FIN). FASEBJ 1992;6:A 2188.
29. Korth R: US Patent No 5.346. 1894-1992.
30. Lekka ME. Tsoukatos D. Kapoulas M: In vivo metabolism of platelet-activating-factor (l-O-alkyl-2-acctyl-sn-giycero-3-phosphocholine) by the protozoanTetrahymena pyriformis.Bio-chirn Biophys Acta 1990:1042:217-220.
31. Roifman CM. Benedict SH. Cheung RK. Gelfand EW: Induction of human B-ccll proliferation and differentiation by the combination of phorbol ester and ionomycin. Eur J Immunol 1987;17:701-710.
32. Korth R. Bidault J. Palmanticr R. Benveniste J. Ninio E: Human platelets release a PAF-acether: Acetylhydrolase similar to that in plasma. Lipids 1993;28:193-199.
33. Tamura G, Takishima T, Mue S, Makino S, Itolt K. Miyamoto T, Shida T, Nakajima S: Effect of a potent PAF receptor antagonist. WEB 2086, on asthma: A multicenter, double blind, placebo-controlled study (abstract 37). 5th International Congress on Platelet-Activating Factor and Related Lipid Mediators. Berlin. 1995.
34. Fradin A. Rothhut B. Poincelot-Canton B. Er-rasfa M. Russo-Marie F: Inhibition of eicosa-noid and PAF formation by dexamethasone in rat inflammatory polymorphonuclear neutrophils may implicate lipocortin “s”. Biochim Biophys Acta 1988;963:248-257.
35. Korth RM: US Patent application No 08 246-476.1992.